Navigation Links
Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
Date:5/19/2011

SOUTH SAN FRANCISCO, Calif., May 19, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.  The primary endpoint, overall response rate (ORR) (defined as partial response or greater) was 24 percent with a median duration of response (DOR) of 7.8 months.  Patients entered the study after receiving a median of five prior lines of therapy (corresponding to a median of 13 anti-myeloma agents). The median overall survival (OS) for all patients in the study, regardless of response to drug, was 15.6 months. Overall survival for the best responding patients (partial response or greater) is continuing to mature (subject to additional patient observations) and is currently 20.7 months.  These data are being presented at the upcoming 47th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by David Siegel, M.D., Ph.D., Division Chief for Myeloma at John Theurer Cancer Center at Hackensack University Medical Center, June 3 – 7, 2011.

Based on the full 003-A1 results, Onyx intends to submit a New Drug Application (NDA) filing for accelerated approval in the July/August timeframe.

"As expected, studies mature and results are updated with minor variability in data observed," said Ted Love, M.D., Executive Vice President, R&D and Technical Operations.  "We are particularly pleased to see the overall survival trend improving for the best responding patients.  Onyx looks forward to filing an NDA in the July to August timeframe based on the positive findings in the 003-A1 s
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Johnson & Johnson to Host Pharmaceuticals Business Review
2. Unilife to Present at the 2011 UBS Global Specialty Pharmaceuticals Conference in London
3. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
4. Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
5. Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting
6. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
7. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
8. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
9. Xanodyne Pharmaceuticals Appoints New Chief Operating Officer
10. Access Pharmaceuticals Provides Update on MuGard Commercial Activities
11. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... BOULDER, Colo. , July 6, 2015 /PRNewswire/ ... inhibitor, encorafenib, was showcased this past weekend at ... during an oral presentation.  At the meeting, data ... preliminary data from a 100-patient randomized Phase 2 ... encorafenib and cetuximab, an EGFR inhibitor, with or ...
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. , ... AGN ), a leading global pharmaceutical company, and Oculeve, ... treatments for dry eye disease, today announced that they ... acquire Oculeve in an all-cash transaction.  Under the terms ... $125 million upfront payment and commercialization milestone payments related ...
(Date:7/6/2015)... /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... its board of directors has received a preliminary non-binding ... Zhang , chairman of the board of directors of ... investment vehicle wholly owned by Mr. Zhang(" Neptunus Holding ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
... HILL, N.C., Aug. 24 TSI Healthcare, a local ... customized technology solutions for physician practices, was recognized for ... 100 Vendors" 2010 annual listing. TSI is ranked among ... including Microsoft® (#47), Dell™ (#2), NextGen Healthcare® (#29), 3M ...
... NacTel (North Atlantic Communications), a leading provider of ... and integrated a new state-of-the-art customer communications system ... the fastest growing durable medical equipment companies in ... set to serve its customers, and chose the ...
Cached Medicine Technology:TSI Healthcare Again Recognized in "Healthcare Informatics TOP 100" 2Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 2Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 3Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 4
(Date:7/6/2015)... ... July 06, 2015 , ... Human ... drug discovery. iPSCs are generated from adult cells, such as blood or skin, ... in the human body. , iPSC-derived cardiomyocytes have proven valuable ...
(Date:7/6/2015)... ... 06, 2015 , ... PristineHydro ( http://www.pristinewaterfilters.com ) has developed ... impurities; it also properly mineralizes the water with electrolyte salts.  Common tap water ... contaminants are a byproduct of how the water is treated chemically.  In response, ...
(Date:7/6/2015)... ... 06, 2015 , ... University of Pittsburgh Cancer Institute (UPCI) scientists ... to reflect newly available tests that better incorporate personalized medicine into diagnosing the condition. ... cancer tests is published in the July issue of the scientific journal Thyroid ...
(Date:7/6/2015)... ... ... a report titled “ Female Hair Loss Needs to be Talked About, Shed Stigma, Experts ... the U.S. will suffer from thinning hair or hair loss . For these 30 million ... beauty queen, who was interviewed for the report began losing her hair at age 11 due ...
(Date:7/6/2015)... ... 06, 2015 , ... Acara Partners, a leading business team ... its complimentary educational webinar series for the summer of 2015. ... their clients through targeted marketing, sales, digital communications, branding and business development programs. ...
Breaking Medicine News(10 mins):Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3
... new cases of malaria are reported each year. However, ... from Leeds, //with funding from the Bill & Melinda ... protection from the disease. ,Design lecturer Dr ... Xeroshield at the Roslin Biocentre will develop a precisely ...
... in the June issue of the Journal of Family Psychology ... their life// and it is important that the baby's security ... sometimes it's difficult for parents to deal with their child's ... of human and community development. "A mother may become anxious ...
... British Journal of Psychology showed that men find heavier women ... wanted to test their theory linking appetite and sexual preference ... women. ,Dr Viren Swami from Liverpool University's ... University conducted the study among 60 university students. Half ...
... conducted by University of Cincinnati on skin cancers has revealed ... skin cancer, and when they do get //it they are ... diagnosis is usually done at an advanced stage. ... Dermatology by Dr. Hugh Gloster, Dermatologist at University of Cincinnati, ...
... new vehicle for delivering radioactive iodine dose to cure ... ,Synthetic scorpion venom is used as carriers ... trials is successfully complete and was conducted by under ... Center's Maxine Dunitz Neurosurgical Institute. About 18 patients participated ...
... among praying mantids – that is, the female praying ... ,However, the possibility that males may also have something ... resolved experimentally. In a paper in the August issue ... (SUNY-Fredonia), study male risk-taking behavior in a praying mantis ...
Cached Medicine News:Health News:Revolutionary Net To Control Malaria 2Health News:Mother And Child Bond In First Year Of Baby's Life 2Health News:New Carrier Developed To Deliver Drugs to Gliomas 2Health News:New Carrier Developed To Deliver Drugs to Gliomas 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: